FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

In today’s episode, we spoke with Kim A. Reiss Binder, MD, about the August 2026 FDA approval of daraxonrasib (Rasonque) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent systemic therapy. Dr Reiss Binder is the assistant program director of the Hematology/Oncology Fellowship Program and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania in Philadelphia.

In our exclusive interview, Dr Binder discussed the significance of this approval, key efficacy data from the pivotal phase 3 RASolute 302 trial (NCT06625320), and the importance of continuing to build off of treatment advances to drive clinical research and improve patient outcomes in this field.